Literature DB >> 11139309

Photodynamic diagnosis of breast tumours after oral application of aminolevulinic acid.

D P Ladner1, R A Steiner, J Allemann, U Haller, H Walt.   

Abstract

Photodynamic diagnosis is of increasing interest for diagnosis in oncology. It is based on a more intense incorporation of a fluorescent dye in tumours compared to normal tissue. As a feasibility study we investigated the effectiveness of oral application of 5-aminolevulinic acid for photodynamic diagnosis of human primary mammary tumours. The study included 16 patients with palpable breast tumours. Aminolevulinic acid was administered at a concentration of 40 mg kg(-1)bodyweight 150-420 min prior to tumourectomy. Intraoperatively blue light (405 nm) was applied to the operation site. Sections of the excised tumour and some lymph nodes were prepared and analysed with a fluorescent microscope. All primary mammary tumour tissues showed significantly higher fluorescence intensity than surrounding normal mammary tissue. Fluorescence of the mammary tumours could also be discriminated macroscopically and intraoperatively. Fluorescence intensity in nonmetastatic lymph node tissue was higher in 2 out of 3 patients than in primary tumour tissue. By photodynamic diagnosis using aminolevulinic acid we were able to reliably distinguish primary mammary tumours from normal mammary tissue microscopically and macroscopically in all our patients. We suggest that photodynamic diagnosis with aminolevulinic acid for breast tumours should be further investigated and developed for intraoperative use and may well be a simple tool for better intraoperative diagnosis and recognition of tumour margins. We hypothesize that lymph node metastasis of breast tumours will not be detectable by this method. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139309      PMCID: PMC2363621          DOI: 10.1054/bjoc.2000.1532

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

Review 1.  How does photodynamic therapy work?

Authors:  B W Henderson; T J Dougherty
Journal:  Photochem Photobiol       Date:  1992-01       Impact factor: 3.421

2.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.

Authors:  J C Kennedy; R H Pottier; D C Pross
Journal:  J Photochem Photobiol B       Date:  1990-06       Impact factor: 6.252

3.  Heme biosynthesis in human breast cancer--mimetic "in vitro" studies and some heme enzymic activity levels.

Authors:  N M Navone; C F Polo; A L Frisardi; N E Andrade; A M Battle
Journal:  Int J Biochem       Date:  1990

4.  An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer.

Authors:  S A Khan; T J Dougherty; T S Mang
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 5.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy.

Authors:  J C Kennedy; R H Pottier
Journal:  J Photochem Photobiol B       Date:  1992-07-30       Impact factor: 6.252

6.  Clinical measurement of tumor fluorescence using a new diagnostic system with hematoporphyrin derivative, laser photoradiation, and a spectroscope.

Authors:  H Kato; K Aizawa; J Ono; C Konaka; N Kawate; K Yoneyama; K Kinoshita; K Nishimiya; H Sakai; M Noguchi
Journal:  Lasers Surg Med       Date:  1984       Impact factor: 4.025

Review 7.  Photodynamic therapy.

Authors:  T J Dougherty; S L Marcus
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma.

Authors:  Q Peng; J Moan; T Warloe; J M Nesland; C Rimington
Journal:  Int J Cancer       Date:  1992-09-30       Impact factor: 7.396

9.  Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid.

Authors:  M Kriegmair; R Baumgartner; R Knuechel; P Steinbach; A Ehsan; W Lumper; F Hofstädter; A Hofstetter
Journal:  Urology       Date:  1994-12       Impact factor: 2.649

10.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Authors:  C S Loh; A J MacRobert; J Bedwell; J Regula; N Krasner; S G Bown
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  12 in total

1.  Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma.

Authors:  Cristian Urla; Sorin Armeanu-Ebinger; Jörg Fuchs; Guido Seitz
Journal:  Surg Endosc       Date:  2014-08-23       Impact factor: 4.584

2.  Preferential accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in breast cancer: a comprehensive study on six breast cell lines with varying phenotypes.

Authors:  Stacy R Millon; Julie H Ostrander; Siavash Yazdanfar; J Quincy Brown; Janelle E Bender; Anita Rajeha; Nirmala Ramanujam
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

3.  Photosensitizer delivery to vulnerable atherosclerotic plaque: comparison of macrophage-targeted conjugate versus free chlorin(e6).

Authors:  Ahmed Tawakol; Ana P Castano; Florencia Anatelli; Gregory Bashian; Jeremy Stern; Touqir Zahra; Faten Gad; Stephanie Chirico; Atosa Ahmadi; Alan J Fischman; James E Muller; Michael R Hamblin
Journal:  J Biomed Opt       Date:  2006 Mar-Apr       Impact factor: 3.170

4.  Use of the dietary supplement 5-aminiolevulinic acid (5-ALA) and its relationship with glucose levels and hemoglobin A1C among individuals with prediabetes.

Authors:  Beatriz L Rodriguez; J David Curb; James Davis; Terry Shintani; Michael H Perez; Noelani Apau-Ludlum; Crystal Johnson; Rosanne C Harrigan
Journal:  Clin Transl Sci       Date:  2012-06-01       Impact factor: 4.689

5.  Photodynamic detection of diseased axillary sentinel lymph node after oral application of aminolevulinic acid in patients with breast cancer.

Authors:  K A Frei; H M Bonel; H Frick; H Walt; R A Steiner
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

6.  Early neoplastic and metastatic mammary tumours of transgenic mice detected by 5-aminolevulinic acid-stimulated protoporphyrin IX accumulation.

Authors:  A M Dorward; K S Fancher; T M Duffy; W G Beamer; H Walt
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

7.  Vitamin D enhances the efficacy of photodynamic therapy in a murine model of breast cancer.

Authors:  Kishore R Rollakanti; Sanjay Anand; Edward V Maytin
Journal:  Cancer Med       Date:  2015-02-25       Impact factor: 4.452

8.  Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial.

Authors:  Kathryn Ottolino-Perry; Anam Shahid; Stephanie DeLuca; Viktor Son; Mayleen Sukhram; Fannong Meng; Zhihui Amy Liu; Sara Rapic; Nayana Thalanki Anantha; Shirley C Wang; Emilie Chamma; Christopher Gibson; Philip J Medeiros; Safa Majeed; Ashley Chu; Olivia Wignall; Alessandra Pizzolato; Cheryl F Rosen; Liis Lindvere Teene; Danielle Starr-Dunham; Iris Kulbatski; Tony Panzarella; Susan J Done; Alexandra M Easson; Wey L Leong; Ralph S DaCosta
Journal:  Breast Cancer Res       Date:  2021-07-12       Impact factor: 6.466

9.  ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.

Authors:  Pratheeba Palasuberniam; Xue Yang; Daniel Kraus; Patrick Jones; Kenneth A Myers; Bin Chen
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

10.  Her2 oncogene transformation enhances 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response.

Authors:  Xue Yang; Pratheeba Palasuberniam; Kenneth A Myers; Chenguang Wang; Bin Chen
Journal:  Oncotarget       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.